Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with β-thalassemia major

被引:27
作者
Wu, Kang-Hsi
Chang, Jan-Gowth
Ho, Yung-Jen
Wu, Shu-Fen
Peng, Ching-Tien
机构
[1] China Med Univ Hosp, Dept Pediat, Taichung 404, Taiwan
[2] China Med Univ Hosp, Dept Mol Med, Taichung 404, Taiwan
[3] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
关键词
glutathione S-transferase M1 (GSTM1); glutathione S-transferase T1 (GSTT1); polymorphism(s); beta-thalassemia (thal) major;
D O I
10.1080/03630260600642575
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Patients with beta-thalassemia (thal) major are subject to Peroxidative tissue injury by iron overload. Glutathione S-transferases work as antioxidants, and their activity is determined genetically. In this study, we used)multiplex polymerase chain reaction (m-PCR) to analyze polymorphism's of two endogenous antioxidant, agents, glutathione S-transferase M1 (GSTM1) and, glutathione S-transferase T1 (GSTT1), and to determine their roles in 41 patients with beta-thal major. Our results showed that the GSTM1 and GSTT1 null genotypes were not associated with any incidence of endocrine dysfunction (including diabetes mellitus, hypogonadism, hypothyroidism, and growth hormone deficiency), liver function, or impaired left ventricular ejection fraction (LVET). The GSTM1 null genotype, but not the GSTT1 null genotype, was associated with a decreased signal intensity ratio on cardiac magnetic resonance imaging (MRI). Our results suggest that genetic variations of the GSTM1 enzyme are associated with cardiac iron deposition in patients with beta-thal major.
引用
收藏
页码:251 / 256
页数:6
相关论文
共 14 条
[1]
ALDOURI MA, 1990, ACTA HAEMATOL-BASEL, V84, P113
[2]
CHEN CM, 2000, MID TAIWAN J MED, V5, P181
[3]
ENZYMATIC DEFENSES OF THE MOUSE HEART AGAINST REACTIVE OXYGEN METABOLITES - ALTERATIONS PRODUCED BY DOXORUBICIN [J].
DOROSHOW, JH ;
LOCKER, GY ;
MYERS, CE .
JOURNAL OF CLINICAL INVESTIGATION, 1980, 65 (01) :128-135
[4]
HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
[5]
NONSPECIFIC SERUM IRON IN THALASSEMIA - ABNORMAL SERUM IRON FRACTION OF POTENTIAL TOXICITY [J].
HERSHKO, C ;
GRAHAM, G ;
BATES, GW ;
RACHMILEWITZ, EA .
BRITISH JOURNAL OF HAEMATOLOGY, 1978, 40 (02) :255-263
[6]
Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia [J].
Kassab-Chekir, A ;
Laradi, S ;
Ferchichi, S ;
Khelil, AH ;
Feki, M ;
Amri, F ;
Selmi, H ;
Bejaoui, M ;
Miled, A .
CLINICA CHIMICA ACTA, 2003, 338 (1-2) :79-86
[7]
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia [J].
Kolnagou, A ;
Fessas, C ;
Papatryphonas, A ;
Economides, C ;
Kontoghiorghes, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :360-361
[8]
Oxidative stress and antioxidant status in beta-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants [J].
Livrea, MA ;
Tesoriere, L ;
Pintaudi, AM ;
Calabrese, A ;
Maggio, A ;
Freisleben, HJ ;
DArpa, D ;
DAnna, R ;
Bongiorno, A .
BLOOD, 1996, 88 (09) :3608-3614
[9]
Lipid peroxidation and antioxidant status in β-thalassemia [J].
Meral, A ;
Tuncel, P ;
Sürmen-Gür, E ;
Özbek, R ;
Öztürk, E ;
Günay, Ü .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2000, 17 (08) :687-693
[10]
Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan [J].
Peng, CT ;
Chow, KC ;
Chen, JH ;
Chiang, YP ;
Lin, TY ;
Tsai, CH .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (06) :392-397